Boehringer, LLY report data for basal insulin analog
14:34 EDT 11 Jun 2012 | BioCentury
Boehringer Ingelheim GmbH (Ingelheim, Germany) and Eli Lilly and Co. (NYSE:LLY) reported data from two Phase II trials of diabetes therapy LY2605541, a basal insulin analog. In an open-label trial in 137 Type I diabetics, once-daily subcutaneous LY26..
Original Article: Boehringer, LLY report data for basal insulin analog
More From BioPortfolio on "Boehringer, LLY report data for basal insulin analog"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
